DOLOMITE - Safety and effectiveness of DTG use in pregnancy

 

A multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women

 

Indication:  HIV positive women receiving DTG (at least 200 starting or on DTG in the first trimester)

 

Status: Ongoing, closed to recruitment

​

Phase: IV

​

Sites: 24

​

Territories : 8

​

 

 

​

Poster : AIDS 2022

Title : A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: Data from DOLOMITE NEAT ID network Study 

Authors : Justyna D. Kowalska1, Sergii Antoniak2, Lambert Assoumou3, Anton Pozniak4, Tetiana Rybak5, Stephane De Wit6 , Ana Milinkovic4, Sherie Roedling7, Annie Duffy8, Carl Fletcher8, Leigh Ragone9, Claire Thorne10, and Vani Vannappagari9

​

Poster Presentation at HIV Glasgow 2022 

Title: A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE-NEAT ID Network study

Authors: Justyna Kowalska, Sergii Antoniak, Lambert Assoumou, Anton Pozniak, Tetiana Rybak, Stephane De Wit, Ana Milinkovic, Sherie Roedling, Carl Fletcher, Leigh Ragone, Claire Thorne, Vani Vannappagari.

 

Combined DOLOMITE-EPICC Poster Presentation at IAS 2026 

Manuscript expected 2027